Cargando…

Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2 Reinfection in Children

Detalles Bibliográficos
Autores principales:	Dowell, Alexander C., Waiblinger, Dagmar, Wright, John, Ladhani, Shamez N., Moss, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303317/ https://www.ncbi.nlm.nih.gov/pubmed/37391077 http://dx.doi.org/10.1016/j.jinf.2023.06.018

Ejemplares similares

Association of Spike-Specific T Cells With Relative Protection From Subsequent SARS-CoV-2 Omicron Infection in Young Children
por: Dowell, Alexander C., et al.
Publicado: (2022)

Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies
por: Schuler, Charles F., et al.
Publicado: (2021)

Infectivity of SARS-CoV-2 and protection against reinfection in rats
por: Yu, Dandan, et al.
Publicado: (2022)

SARS-CoV-2 reinfection with a virus harboring mutation in the Spike and the Nucleocapsid proteins in Panama
por: Díaz, Yamilka, et al.
Publicado: (2021)

Production and Characterization of Monoclonal Antibodies Against the Nucleocapsid Protein of SARS-COV
por: Fang, Ying, et al.
Publicado: (2006)

Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
por: Terry, James S., et al.
Publicado: (2020)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage
por: Kim, Green, et al.
Publicado: (2021)

Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody
por: Terry, James S., et al.
Publicado: (2021)

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
por: Deng, Wei, et al.
Publicado: (2020)

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection
por: Hanrath, Aidan T., et al.
Publicado: (2020)

Duration of immune protection of SARS-CoV-2 natural infection against reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Correction to: Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage
por: Kim, Green, et al.
Publicado: (2022)

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England
por: Mensah, Anna A, et al.
Publicado: (2022)

Protection from infection and reinfection due to the Omicron BA.1 variant in care homes
por: Choudhry, Saher, et al.
Publicado: (2023)

Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV
por: Zhao, Aizhi, et al.
Publicado: (2007)

Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
por: Muir, Luke, et al.
Publicado: (2021)

SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort
por: Finch, Emilie, et al.
Publicado: (2022)

Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
por: Clarke, Candice L., et al.
Publicado: (2021)

Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection
por: Shrestha, Rupendra, et al.
Publicado: (2021)

Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004)

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients
por: Yang, Li, et al.
Publicado: (2021)

Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
por: Dangi, Tanushree, et al.
Publicado: (2022)

An immune correlate of SARS-CoV-2 infection and severity of reinfections
por: Maier, Hannah E., et al.
Publicado: (2021)

Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
por: Yamaoka, Yutaro, et al.
Publicado: (2021)

Immunological imprinting of humoral immunity to SARS-CoV-2 in children
por: Dowell, Alexander C., et al.
Publicado: (2023)

Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
por: Atti, Ana, et al.
Publicado: (2022)

SARS-CoV-2 reinfection()
por: Romera, I., et al.
Publicado: (2021)

Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines
por: Yang, Huijie, et al.
Publicado: (2023)

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020
por: Jeffery-Smith, Anna, et al.
Publicado: (2021)

SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants
por: Kubale, John, et al.
Publicado: (2022)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19
por: Lu, Ruei-Min, et al.
Publicado: (2021)

Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results
por: Perkmann, Thomas, et al.
Publicado: (2021)

Reinfection and reactivation of SARS-CoV-2
por: Dowran, Razieh, et al.
Publicado: (2022)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
por: Parashar, Nidarshana Chaturvedi, et al.
Publicado: (2020)

SARS-CoV-2 symptomatic reinfection among patients with primary antibody deficiency
por: Marcus, Nufar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bul48vr0p7ppapg9vh73e2dbti